%0 Generic
%A Raimondi, A.
%A Morano, F.
%A Trarbach, T.
%A Karthaus, M.
%A Lonardi, S.
%A Fruehauf, S.
%A Cremolini, C.
%A Graeven, U.
%A Bittoni, A.
%A Mueller, L.
%A Bianchi, A. Sartore
%A Aranda, E.
%A Boige, V.
%A Stintzing, S.
%A Di Bartolomeo, M.
%A Koenig, A.
%A Pietrantonio, F.
%A Modest, D.
%T Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials
%D 2022
%@ 0923-7534
%U http://hdl.handle.net/10668/21914
%X Background: In metastatic colorectal cancer (mCRC), after a first-line induction with doublet/triplet chemotherapy plus bevacizumab, fluoropyrimidine+bevacizumab is the recommended maintenance option. The combination of anti-EGFR agents and chemotherapy is a guideline-endorsed first-line option for RAS/BRAF wild-type (wt) mCRC patients, but the optimal maintenance schedule has not been defined, yet. The Valentino trial showed that, after 4-month FOLFOX+panitumumab induction, singleagent  panitumumab induced inferior progression-free survival (PFS) than FUFA+panitumumab, though slightly reducing toxicity. The Panama study demonstrated that, after 3-month FOLFOX+panitumumab induction, FUFA+panitumumab induced a significantly superior PFS than FUFA alone.
%K Panitumumab
%K Bevacizumab
%K Proto-oncogene proteins B-raf
%~